https://www.facebook.com/755530467635823/

Research MedX, Dhaka (2025)

23/08/2025

🩺🔬📚 Another Milestone for Our NAFLD Research Team! 🚑✨

Alhamdulillah! 🙏 We are thrilled to share that our second study on NAFLD has been successfully published in AACE Endocrinology and Diabetes, the official journal of the American Association of Clinical Endocrinology (AACE)! 🎉📖

📌 Title of the study:
Evaluating the Comparative Effectiveness of Sodium-Glucose Transporter 2 Inhibitors in Patients with Nonalcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials

🔎 What we did:
We conducted the first Bayesian Network Meta-Analysis (NMA) comparing different SGLT-2 inhibitors (dapagliflozin, empagliflozin, ipragliflozin) for their effects on both hepatic outcomes (ALT, AST, GGT, FIB-4 score) and metabolic outcomes (body weight, FPG) in NAFLD patients.

📊 Key Findings (SUCRA-based ranking):
⚕️ Dapagliflozin 💊 – Best for reducing ALT (-11.35 IU/L) & body weight (-3.60 kg).
⚕️ Ipragliflozin 💊 – Superior in improving GGT (-15.19 IU/L) & fasting plasma glucose (-2.20 mmol/L).
⚕️ Empagliflozin 💊 – Showed strongest effect on fibrosis marker (FIB-4 score: -0.12).

✨ Clinical Relevance:
Our study demonstrates that SGLT-2 inhibitors significantly improve both liver health and metabolic outcomes 🧪⚖️ in patients with NAFLD. The findings support personalized treatment strategies, where different SGLT-2 inhibitors can be prioritized depending on patient-specific needs (enzymes, fibrosis, weight, or glucose control).

🙏 Acknowledgment:
This work would not have been possible without the tireless dedication of our collaborators, mentors, and peers. We are deeply grateful to everyone who contributed to this journey of advancing liver and metabolic research. 🌍🤝

📖 Our first NAFLD project focused on SGLT2i effects on lipid profiles, and with this second one, we highlight their hepatic enzyme and fibrosis benefits — building a more complete picture of their therapeutic role.

🚀 Stay tuned as we continue our mission to produce impactful research that bridges clinical practice, endocrinology, and evidence based medicine for better patient outcomes! 💡🩺

18/08/2025

📢 Research Update!

Alhamdulillah!!!
Our second project on NAFLD has been officially accepted for publication in AACE Endocrinology and Diabetes — the flagship journal of the American Association of Clinical Endocrinology (AACE)! 🎉

Our work has been a two-step journey:
1️⃣ The first project explored how SGLT2 inhibitors impact lipid profiles in patients with NAFLD.
2️⃣ This second project dives deeper — focusing on hepatic enzyme parameters in NAFLD.

Title:
Evaluating the Comparative Effectiveness of Sodium-Glucose Transporter 2 Inhibitors in Patients with Nonalcoholic Fatty Liver Disease: A Comprehensive Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials

This marks another step forward in addressing the growing global challenge of NAFLD, by identifying potential therapeutic benefits of SGLT2 inhibitors beyond glycemic control.

We are truly grateful to our collaborators, mentors, and peers whose support made this work possible. 🚀

Stay tuned — full text coming soon once published online!

15/08/2025

Alhamdulillah!

Just received the acceptance notification for our AHA25 (American Heart Association 2025 Conference) projects.

Thank you to everyone involved in those projects, and a special thanks to Dr. Mohd Turzo Rahman bhaia, who is a PGY3 IM resident, for the collaboration in his busy schedule and for being the presenter for our accepted abstracts.

These will be presented at the AHA Scientific Sessions 2025, taking place from November 7–10, 2025, at the Ernest N. Morial Convention Center in New Orleans, Louisiana, USA.

After the presentations, they will be published in the prestigious AHA journal, Circulation, which has an impact factor of 40.

This year, the AHA rejection rate is much higher, and most of our collaborators are surprised by this—not just me.

Even our experienced foreign collaborators, who received a good number of acceptances last year, faced significant rejections this year. Some received less than a 10% acceptance rate, which is unthinkable for us since we had more acceptances at ACC, ESC this year. Still, Alhamdulillah!

To all of our collaborators in our group whose abstracts were rejected, please do not get disheartened. The AHA is always competitive, even more so than ACC, ESC and other conferences. There are many good opportunities for us to publish those rejected abstracts elsewhere.

Thank you, everyone, for your continuous support and collaboration!

14/08/2025

We are excited to share that our latest case report has been officially published in PubMed-indexed journal Radiology Case Reports (Vol. 20, Issue 11, November 2025).

🟢Topic of the case: Neurosarcoidosis-Induced Panhypopituitarism with Diabetes Insipidus and Subclinical Multifocal Pneumonitis 🧠💧🫁

🔴Clinical Takeaways

1. Always maintain a high index of suspicion for neurosarcoidosis in patients with unexplained neurological and endocrine symptoms, especially when subtle respiratory findings are present.

2. Early recognition and intervention can prevent permanent pituitary dysfunction and improve quality of life.

3. Multidisciplinary collaboration between neurology, endocrinology, pulmonology, and radiology is crucial in such complex cases.

Heartfelt thanks and gratitude to Samiha Zaman Akhter, apu and Maisha Fairooz, apu for their contributions to preparing this case and for the successful collaboration.

13/08/2025

🔴Seeing our work appear on PubMed is always a deeply satisfying milestone! ✨

🟢Our latest study —
"Demographic and racial disparities in small-cell lung carcinoma: trends in diagnosis to treatment time, chemoradiotherapy seeking, and incidence rates — A SEER database analysis (2000–2021) with Bayesian multilevel regression modeling" (Published on Annals of Medicine and Surgery)— has just been indexed in PubMed.

🔴Indexing in PubMed is more than just a database entry — it reflects the highest standards of research integrity, transparency, and scientific rigor, making the work accessible to clinicians, researchers, and policymakers worldwide. 📚

🟢It usually takes 4–8 weeks (sometimes longer) for a published paper to appear in PubMed after journal publications, so finally seeing it there feels like the last puzzle piece clicking into place! 🧩

07/08/2025

📢 New Publication Alert!

We are pleased to share that our latest cohort study, utilizing the NIH-supported nationwide oncology database (USA), has been officially published in the PubMed-indexed journal Annals of Medicine and Surgery (Vol. 87, No. 8, August 2025)! 🎉

🔬 Study Overview:

Small-cell lung carcinoma (SCLC) is one of the most aggressive lung cancers, with limited survival outcomes. Our research sought to explore whether disparities in race, s*x, and age influence:

Incidence rates of SCLC
Treatment-seeking behavior
Delays in initiating chemotherapy and radiotherapy

📈 Key Findings:

American Indian/Alaska Native individuals had a higher incidence of SCLC (β = 6.47, 95% CI: 5.26–7.69, P < 0.0001), followed by White (β = 4.85, 95% CI: 3.86–5.84, P < 0.0001) and
Black (β = 4.15, 95% CI: 3.12–5.17, P < 0.0001) patients compared to Asian/Pacific Islander patients.

No significant racial disparities were observed in chemotherapy (χ2 = 0.84, df = 6, P = 0.9909), radiotherapy (χ2 = 14.75, df = 27, P = 0.9728), or time to
treatment initiation (χ2 = 12.36, df = 9, P = 0.1938).

Bayesian regression models confirmed higher SCLC incidence in older age
groups (70–74 years: β = 9.62, 95% CrI: [1.77, 17.71]; 75–79 years: β = 12.87, 95% CrI: [5.06, 20.99]; 80–84 years: β = 12.80, 95% CrI: [5.03, 20.89]; 85 + years: β = 8.16, 95% CrI: [0.38, 16.24]) and males (β = 3.77, 95% CrI: [3.37, 4.17], Rhat = 1.00) compared to females.

🧠 Why It Matters:

Our findings confirm and quantify the existence of racial and demographic disparities in the incidence of SCLC, while also showing equitable access to treatment once diagnosed—at least within the SEER-covered population.

🔍 The use of Bayesian modeling allowed for nuanced, probabilistic interpretation of trends, moving beyond traditional regression to better reflect real-world complexities.

📘 Citation:

This study is now available in the August 2025 issue of the Annals of Medicine and Surgery.

📎 For full access, find the link provided below in the comment section.

07/08/2025

As a researcher, one of the most rewarding experiences is receiving an email from the journal regarding the acceptance of a paper or notification that our study just has been published online.

05/08/2025

🔍 Mastering PubMed Literature Searches: A Step-by-Step Guide for Researchers
If you’re serious about publishing high-quality research, knowing how to search PubMed effectively is non-negotiable. Whether you’re drafting a case report, systematic review, or meta-analysis, a thorough literature search forms the backbone of evidence-based work.

Here’s how to do it right, step by step:

🟢 1️⃣ Start with a Clear Research Question
Before you open PubMed, define exactly what you’re looking for.
Use frameworks like PICO:

P: Patient or Problem

I: Intervention

C: Comparison

O: Outcome

Example: Among diabetic patients (P), does metformin (I) compared to insulin (C) reduce mortality (O)?

🟢 2️⃣ Use Keywords and Synonyms
Think of all possible terms authors might have used.
For example:

Diabetes: "Diabetes Mellitus," "Type 2 Diabetes," "T2DM"

Mortality: "Death," "Survival," "Fatal outcome"

Make a list of these synonyms and related terms to broaden your search.

🟢 3️⃣ Use Boolean Operators
Combine terms using AND, OR, and NOT:

AND: Narrows results by requiring all terms.

Metformin AND mortality

OR: Broadens results by including synonyms.

(Metformin OR biguanides) AND mortality

NOT: Excludes unwanted terms.

Metformin AND mortality NOT cancer

🟢 4️⃣ Leverage MeSH Terms
PubMed uses Medical Subject Headings (MeSH)—standardized vocabulary for indexing articles.

Click “MeSH Database” in PubMed to find appropriate headings.

Example MeSH Term: Diabetes Mellitus, Type 2

Searching with MeSH terms improves precision and reduces irrelevant results.

✅ Tip: Combine MeSH with keywords for the best coverage.

🟢 5️⃣ Use Filters to Refine Results
On the left panel of your results page, apply filters:

Article Type: RCTs, Reviews, Meta-Analyses

Publication Date: Last 5 years

Species: Humans

Language: English

This helps narrow thousands of hits to the most relevant papers.

🟢 6️⃣ Use Truncation and Wildcards
Use an asterisk * to search for word variants:

Therap*= therapy, therapies, therapeutic

Use quotation marks for exact phrases:

"Type 2 diabetes mellitus"

🟢 7️⃣ Save and Export Your Results
Use My NCBI to save searches and set alerts for new articles.

Export citations to reference managers like EndNote, Mendeley, or Zotero.

🟢 8️⃣ Example Search Strategy
If you’re researching the impact of metformin on mortality in Type 2 diabetes:

("Diabetes Mellitus, Type 2"[MeSH]) AND ("Metformin"[MeSH] OR metformin[tiab]) AND (mortality[tiab] OR "Death"[MeSH]) AND ("Randomized Controlled Trial"[pt] OR "Cohort Studies"[MeSH])

✅ Why It Matters
A systematic, transparent search:

Strengthens your manuscript.

Impresses peer reviewers.

Minimizes bias in your findings.

At Research MedX, we help researchers master these essential skills to publish impactful, PubMed-indexed papers.

💡 Ready to upgrade your search skills?
Save this post for reference and share it with your team!

02/08/2025

📚✨ Important Medical Databases — Know Where to Search!
Whether you’re working on a case report, systematic review, or original research, understanding where to look is as important as what you’re looking for.

🔍 From PubMed and EMBASE to Web of Science and SCOPUS, each database has unique strengths and limitations.

✅ Save this guide to pick the right tool for your next literature search, improve the quality of your evidence, and make your work stand out.

💡 Tip: Combining searches across multiple databases ensures you don’t miss critical studies.

01/08/2025

📊 Common Statistical Tests Every Researcher Should Know:
If you're publishing clinical research — whether a original article, or audit — understanding the right statistical test is not optional. It's essential.

Misuse of stats = flawed conclusions, rejected papers, and wasted effort.

Here’s your beginner-friendly guide to three of the most commonly used statistical tests in medicine and public health research:

☕️ 1️⃣ t-test — “Tea is for Two”
🔍 Purpose: To compare the means of two independent groups on a continuous outcome (e.g., blood pressure, cholesterol, weight).
✅ Used when:

Your outcome variable is continuous (measurable: like BP, glucose, etc.)

You have two independent groups

The data is roughly normally distributed

🧠 Example:
Comparing the mean systolic blood pressure between male and female patients.

📌 Variations:

Unpaired t-test for two separate groups

Paired t-test for comparing the same group before and after an intervention (e.g., pre- and post-treatment HbA1c in diabetic patients)

🎯 Goal: Is the difference in means due to chance, or is it statistically significant?

🧪 2️⃣ ANOVA — ANalysis Of VAriance
🔍 Purpose: To compare the means of three or more groups
✅ Used when:

You have one continuous outcome

There are three or more independent groups

You're interested in knowing if any of the group means differ significantly

🧠 Example:
Comparing the mean hemoglobin levels among patients of three different ethnicities, or the mean hospital stay among four different surgical techniques.

📌 Important Note:
ANOVA tells you that a difference exists, but not where it is.
You’ll need post-hoc tests (like Tukey’s HSD) to find out which specific groups differ.

🎓 Think of ANOVA as the upgrade to t-test when you're dealing with more than two groups.

🔲 3️⃣ Chi-Square Test (χ²) — Think “Chi-tegorical”
🔍 Purpose: To compare proportions or percentages across categories
✅ Used when:

Your variables are categorical (like Yes/No, Male/Female, Present/Absent)

You’re comparing two or more groups

🧠 Example:
Checking whether the proportion of patients with hypertension differs among three age groups (e.g., 60 years).

📌 Important Tip:
If your sample size is small or the expected frequency in any cell is

29/07/2025

📊 Understanding Regression: A Must-Know for Every Researcher!
Whether you’re exploring clinical outcomes, predicting lab values, or modeling patient behavior — regression analysis is a core statistical tool in medical and scientific research.

Here’s a quick guide to 3 essential types of regression you should know:

1️⃣ Simple Linear Regression
👉 Used when analyzing the relationship between one independent variable and one dependent (target) variable.
📈 Perfect when your goal is to explore a straight-line relationship between two variables.

🧠 Example: Predicting systolic blood pressure based on age.

2️⃣ Multiple Linear Regression
👉 Ideal when you want to understand the effect of two or more independent variables on a single outcome.
🔍 This is your go-to when research questions involve multifactorial relationships.

🧠 Example: Predicting HbA1c based on age, BMI, and medication adherence.

3️⃣ Polynomial Regression
👉 Useful when the relationship between variables is non-linear. By including polynomial terms (e.g., x², x³), this method models curved trends in the data.

📌 Important Note:
Even though polynomial regression models non-linear patterns, it is still considered a linear regression model — because it remains linear in its coefficients.
This distinction is crucial for accurate model interpretation!

🧠 Example: Modeling disease progression over time when the change is not linear.

💡 Mastering regression isn’t just for statisticians.
In today’s evidence-based world, it's essential for clinicians, researchers, and students who want to ask better questions and find clearer answers.

28/07/2025

📚 Worried About Article Processing Charges/ Article Publication Charges (APCs)?
You’re Not Alone!

As researchers from low- and middle-income countries 🌍 like Bangladesh, we often hesitate to submit to top-tier open-access journals because of one major barrier:

🚨 APCs (Article Processing Charges) can be shockingly high — sometimes $2000, $3000, or even $5000 USD per article! 😱

But here’s the good news:

👉 Most leading publishers offer full or partial APC waivers for authors from eligible countries — and many of us qualify!

✅ Publishers that provide APC waivers or discounts:
🔹 Elsevier
🔹 Wiley
🔹 Springer Nature
🔹 Lippincott Williams & Wilkins (LWW)
🔹 ...and many more!

📌 For example:

We recently received a full APC waiver from Wiley’s Cancer Reports journal — just by accurately completing the waiver section during submission and confirming affiliation with an eligible country.
And the good news is we have got APC waiver in all of our previous submissions.

💡 Tips to Maximize Your Chances of Getting an APC Waiver:

1️⃣ Apply for the waiver during the initial submission
2️⃣ Clearly state your affiliation and country during submission
3️⃣ Avoid changing the corresponding author post-submission — this can affect eligibility!

🌟 Don't let high APCs silence your research.

If your manuscript is strong, submit it with confidence and apply for the APC waiver. Many journals are actively supporting voices from underrepresented regions.

Research MedX

23/08/2025

18/08/2025

15/08/2025

14/08/2025

13/08/2025

07/08/2025

07/08/2025

05/08/2025

02/08/2025

01/08/2025

29/07/2025

28/07/2025

Address

Website

Alerts

Shortcuts

Share

Category